MannKind Corporation (NASDAQ:MNKD) ranks fifth among the 10 Best Biotech Stocks to Buy Under $10. The company focuses on developing inhaled therapeutic products for endocrine and orphan lung diseases, such as Afrezza, a rapid-acting inhaled insulin. MNKD recently submitted a sBLA to the FDA for pediatric Afrezza use, with positive Phase 3 trial data supporting its efficacy.

MNKD is advancing its orphan lung disease portfolio with MNKD-101 and MNKD-201 targeting NTM lung disease and IPF, respectively. The company secured up to $500 million in financing to support the pediatric Afrezza rollout and accelerate clinical programs. MNKD also explores artificial intelligence to optimize product delivery systems.

The U.S.-based manufacturing facility in Danbury, Connecticut, supports MNKD’s revenue generation and pipeline production. The company’s revenue is bolstered by royalties from Tyvaso DPI, an inhaled therapy for pulmonary arterial hypertension. MNKD presents investment potential, but some AI stocks may offer greater upside potential and lower downside risk.

For more insights on investment opportunities, check out our free report on the best short-term AI stock.

Read more at Yahoo Finance: MannKind Corporation (MNKD) Seeks FDA Pediatric Approval for Afrezza